Abstract: A system and method to identify filler speech and deliver real-time feedback to the speaker for correction. The system receives a live audio signal from a user's speech, analyzes the audio signal for filler speech, verifies the speaker's identity, and, if filler speech is detected from the verified user, provides discreet sensory feedback to make the speaker aware of this behavior so it can be corrected in real time with the added benefit of helping the speaker to improve their speech behavior by eliminating the use of filler speech.

Abstract: Disclosed herein are a catheter assembly and method of applying a catheter assembly. In an example, the catheter assembly can include a catheter body and frame member extending between proximal and distal portions, the frame member having a first mechanical characteristic, and a floating sleeve coupled around the frame member and extending between the proximal and distal portions, the floating sleeve having a second mechanical characteristic different than the first mechanical characteristic. The floating sleeve can include at least one floating segment and one or more anchor segments along the catheter body. The at least one floating segment of the floating sleeve can be moveable relative to the frame member, and the one or more anchor segments of the floating sleeve can be interconnected with the frame member.

Abstract: Stiffening apparatus (FIG. 1) A stiffening apparatus (10) for use with a suspension assembly (12) is disclosed. The stiffening apparatus (10) comprises a suspension assembly (68) configured for receiving a first part of the suspension assembly (12). The stiffening apparatus (10) further includes a holder (70) extending transverse to the suspension assembly (68). The holder (70) is configured for receiving a second part of the suspension assembly (12). The holder (70) secures the stiffening apparatus (10) to the suspension assembly (12).

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g.

Abstract: The present invention relates to attenuated African Swine Fever viruses. The attenuated viruses protect pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent African Swine Fever.

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.

Abstract: Discussed herein are various embodiments related to a catheter assembly. The catheter assembly can include a catheter body extending between a proximal portion and a distal portion. The catheter body can include a sleeve and a hypotube, connected by at least one bond site, and separated by a floating gap. The hypotube can include at least one flow opening extending from the hypotube lumen to a stagnation zone, configured to permit flow between the stagnation zone and the hypotube lumen.

Abstract: A suspension assembly (10) comprising: a support member (12) for supporting an item; an elongate suspension article (14) defining a securing opening (30); and a securing device (16) on the support member (12). The support member (12) defines an aperture (38) through which the suspension article (14) can be inserted. The securing device (16) has a securing member (68) movable across the aperture (38) between a securing position and a non-securing position. The securing member (68) is receivable through the securing opening (30) in the suspension article (14) to secure the support member (12) to the suspension article (14) when the suspension article (14) is received through the aperture (38) and the securing member (68) is in the securing position.

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.

Abstract: A connecting device (10) comprises a first securing arrangement (16) for securing a first elongate article (12) to the connecting device (10). The first elongate article (12) is secured in a first orientation. The connecting device (10) comprises a second securing arrangement (18) for securing a second elongate article (14) to the connecting device (10). The second elongate article (14) is secured in a second orientation. The second orientation is transverse to the first orientation.

Abstract: Disclosed herein are a catheter assembly and method of applying a catheter assembly. In an example, the catheter assembly can include a catheter body and frame member extending between proximal and distal portions, the frame member having a first mechanical characteristic, and a floating sleeve coupled around the frame member and extending between the proximal and distal portions, the floating sleeve having a second mechanical characteristic different than the first mechanical characteristic. The floating sleeve can include at least one floating segment and one or more anchor segments along the catheter body. The at least one floating segment of the floating sleeve can be moveable relative to the frame member, and the one or more anchor segments of the floating sleeve can be interconnected with the frame member.

Abstract: A connecting device (10) comprises a first securing arrangement (16) for securing a first elongate article (12) to the connecting device (10). The first elongate article (12) is secured in a first orientation. The connecting device (10) comprises a second securing arrangement (18) for securing a second elongate article (14) to the connecting device (10). The second elongate article (14) is secured in a second orientation. The second orientation is transverse to the first orientation.